Dapagliflozin in Heart Failure: A Comprehensive Meta-analysis on Functional Capacity, Symptoms, and Safety Outcomes.
Journal
American journal of cardiovascular drugs : drugs, devices, and other interventions
ISSN: 1179-187X
Titre abrégé: Am J Cardiovasc Drugs
Pays: New Zealand
ID NLM: 100967755
Informations de publication
Date de publication:
11 Sep 2024
11 Sep 2024
Historique:
accepted:
22
07
2024
medline:
12
9
2024
pubmed:
12
9
2024
entrez:
11
9
2024
Statut:
aheadofprint
Résumé
To evaluate the comparative effects of dapagliflozin versus placebo in patients with heart failure (HF), focusing on functional capacity, symptoms, and safety outcomes. Despite advancements in heart failure (HF) therapy, HF is still a significant cause of recurrent hospitalization and death worldwide. Dapagliflozin has demonstrated potential in lowering hospitalizations and mortality associated with heart failure; however, its impact on functional capacity, particularly the 6-min walk distance (6MWD), and the comprehensive assessment of safety outcomes in diverse HF populations, including those with preserved or reduced ejection fraction (HFpEF and HFrEF, respectively), requires further investigation. PubMed, Web of Science, Cochrane Library, and Scopus databases were comprehensively searched to identify randomized controlled trials (RCTs) investigating the efficacy of dapagliflozin in comparison with control interventions for heart failure. The primary outcome was a change in the 6MWD, KCCQ score, and safety measures included hospitalization, all-cause mortality, and adverse events. In our meta-analysis of ten studies involving 12,695 patients with heart failure, dapagliflozin showed significantly improved Kansas City Cardiomyopathy Questionnaire (KCCQ) scores [risk ratio (RR) of 2.75, 95% confidence interval (CI) (1.95-3.569), p < 0.00001] and no significant differences in 6-min walk distance [6MWD; RR of 3.59, 95% CI (- 1.44 to 8.63), p = 0.16]. Dapagliflozin demonstrated a notable reduction in hospitalization for heart failure [RR of 0.76, 95% CI (0.68-0.84), p < 0.00001], significant overall reduction on the effect of any cause mortality [RR of 0.90, 95% CI (0.83-0.99), p = 0.03). There was, however, no significant effect on adverse events [RR of 0.96, 95% CI (0.98-1.03), p = 0.39). Our meta-analysis of ten trials concluded that dapagliflozin significantly improved KCCQ scores in both HFrEF and HFpEF. The improvement in 6MWD was not statistically significant but trended toward dapagliflozin. Dapagliflozin also showed a mortality benefit in patients with reduced ejection fraction; however, in patients with preserved ejection fraction, the result was not statistically significant. There was also a statistically significant reduction in heart failure hospitalizations across all classes.
Sections du résumé
OBJECTIVE
OBJECTIVE
To evaluate the comparative effects of dapagliflozin versus placebo in patients with heart failure (HF), focusing on functional capacity, symptoms, and safety outcomes.
BACKGROUND
BACKGROUND
Despite advancements in heart failure (HF) therapy, HF is still a significant cause of recurrent hospitalization and death worldwide. Dapagliflozin has demonstrated potential in lowering hospitalizations and mortality associated with heart failure; however, its impact on functional capacity, particularly the 6-min walk distance (6MWD), and the comprehensive assessment of safety outcomes in diverse HF populations, including those with preserved or reduced ejection fraction (HFpEF and HFrEF, respectively), requires further investigation.
METHODS
METHODS
PubMed, Web of Science, Cochrane Library, and Scopus databases were comprehensively searched to identify randomized controlled trials (RCTs) investigating the efficacy of dapagliflozin in comparison with control interventions for heart failure. The primary outcome was a change in the 6MWD, KCCQ score, and safety measures included hospitalization, all-cause mortality, and adverse events.
RESULTS
RESULTS
In our meta-analysis of ten studies involving 12,695 patients with heart failure, dapagliflozin showed significantly improved Kansas City Cardiomyopathy Questionnaire (KCCQ) scores [risk ratio (RR) of 2.75, 95% confidence interval (CI) (1.95-3.569), p < 0.00001] and no significant differences in 6-min walk distance [6MWD; RR of 3.59, 95% CI (- 1.44 to 8.63), p = 0.16]. Dapagliflozin demonstrated a notable reduction in hospitalization for heart failure [RR of 0.76, 95% CI (0.68-0.84), p < 0.00001], significant overall reduction on the effect of any cause mortality [RR of 0.90, 95% CI (0.83-0.99), p = 0.03). There was, however, no significant effect on adverse events [RR of 0.96, 95% CI (0.98-1.03), p = 0.39).
CONCLUSIONS
CONCLUSIONS
Our meta-analysis of ten trials concluded that dapagliflozin significantly improved KCCQ scores in both HFrEF and HFpEF. The improvement in 6MWD was not statistically significant but trended toward dapagliflozin. Dapagliflozin also showed a mortality benefit in patients with reduced ejection fraction; however, in patients with preserved ejection fraction, the result was not statistically significant. There was also a statistically significant reduction in heart failure hospitalizations across all classes.
Identifiants
pubmed: 39261443
doi: 10.1007/s40256-024-00669-x
pii: 10.1007/s40256-024-00669-x
doi:
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Metra M, Carubelli V, Ravera A, Stewart Coats AJ. Heart failure 2016: still more questions than answers. Int J Cardiol. 2016;227:766–77. https://doi.org/10.1016/j.ijcard.2016.10.060 .
doi: 10.1016/j.ijcard.2016.10.060
pubmed: 27838123
Mentz RJ, Kelly JP, von Lueder TG, Voors AA, Lam CS, Cowie MR, et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol. 2014;64(21):2281–93. https://doi.org/10.1016/j.jacc.2014.08.036 .
doi: 10.1016/j.jacc.2014.08.036
pubmed: 25456761
pmcid: 4254505
Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34(1):29–34. https://doi.org/10.1016/0002-9149(74)90089-7 .
doi: 10.1016/0002-9149(74)90089-7
pubmed: 4835750
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28. https://doi.org/10.1056/NEJMoa1504720 .
doi: 10.1056/NEJMoa1504720
pubmed: 26378978
Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57. https://doi.org/10.1056/NEJMoa1611925 .
doi: 10.1056/NEJMoa1611925
pubmed: 28605608
Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57. https://doi.org/10.1056/NEJMoa1812389 .
doi: 10.1056/NEJMoa1812389
pubmed: 30415602
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306. https://doi.org/10.1056/NEJMoa1811744 .
doi: 10.1056/NEJMoa1811744
pubmed: 30990260
McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, DAPA-HF Trial Committees and Investigators, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995–2008. https://doi.org/10.1056/NEJMoa1911303 .
doi: 10.1056/NEJMoa1911303
pubmed: 31535829
Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, EMPEROR-Reduced Trial Investigators, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413–24. https://doi.org/10.1056/NEJMoa2022190 .
doi: 10.1056/NEJMoa2022190
pubmed: 32865377
Anker SD, Butler J, Filippatos G, Shahzeb Khan M, Ferreira JP, Bocchi E, Böhm M, Brunner-La Rocca HP, Choi DJ, Chopra V, EMPEROR-Preserved Trial Committees and Investigators, et al. Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial. Eur J Heart Fail. 2020;22:2383–92. https://doi.org/10.1002/ejhf.2064 .
doi: 10.1002/ejhf.2064
pubmed: 33251670
Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, DELIVER Trial Committees and Investigators, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387:1089–98. https://doi.org/10.1056/NEJMoa2206286 .
doi: 10.1056/NEJMoa2206286
pubmed: 36027570
Jhund PS, Kondo T, Butt JH, Docherty KF, Claggett BL, Desai AS, Vaduganathan M, Gasparyan SB, Bengtsson O, Lindholm D, et al. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nat Med. 2022;28:1956–64. https://doi.org/10.1038/s41591-022-01971-4 .
doi: 10.1038/s41591-022-01971-4
pubmed: 36030328
pmcid: 9499855
Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive metaanalysis of five randomised controlled trials. Lancet. 2022;400:757–67. https://doi.org/10.1016/S0140-6736(22)01429-5 .
doi: 10.1016/S0140-6736(22)01429-5
pubmed: 36041474
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure. J Cardiac Fail. 2022;28(5):e1–167. https://doi.org/10.1016/j.cardfail.2022.02.009 .
doi: 10.1016/j.cardfail.2022.02.009
Fiuzat M, Lowy N, Stockbridge N, Sbolli M, Latta F, Lindenfeld J, Lewis EF, Abraham WT, Teerlink J, Walsh M, et al. Endpoints in heart failure drug development: history and future. JACC Heart Fail. 2020;8:429–40. https://doi.org/10.1016/j.jchf.2019.12.011 .
doi: 10.1016/j.jchf.2019.12.011
pubmed: 32278679
Zannad F, Garcia AA, Anker SD, Armstrong PW, Calvo G, Cleland JG, Cohn JN, Dickstein K, Domanski MJ, Ekman I, et al. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. Eur J Heart Fail. 2013;15:1082–94. https://doi.org/10.1093/eurjhf/hft095 .
doi: 10.1093/eurjhf/hft095
pubmed: 23787718
Nassif ME, Windsor SL, Tang F, Khariton Y, Husain M, Inzucchi SE, McGuire DK, Pitt B, Scirica BM, Austin B, et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial. Circulation. 2019;140:1463–76. https://doi.org/10.1161/1161/CIRCULATIONAHA.119.042929 .
doi: 10.1161/1161/CIRCULATIONAHA.119.042929
pubmed: 31524498
Abraham WT, Lindenfeld J, Ponikowski P, Agostoni P, Butler J, Desai AS, Filippatos G, Gniot J, Fu M, Gullestad L, et al. Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. Eur Heart J. 2021;42:700–10. https://doi.org/10.1093/eurheartj/ehaa943 .
doi: 10.1093/eurheartj/ehaa943
pubmed: 33351892
Nassif ME, Windsor SL, Borlaug BA, Kitzman DW, Shah SJ, Tang F, Khariton Y, Malik AO, Khumri T, Umpierrez G, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021;27:1954–60. https://doi.org/10.1038/s41591-021-01536-x .
doi: 10.1038/s41591-021-01536-x
pubmed: 34711976
pmcid: 8604725
Spertus JA, Birmingham MC, Nassif M, Damaraju CV, Abbate A, Butler J, Lanfear DE, Lingvay I, Kosiborod MN, Januzzi JL. The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. Nat Med. 2022;28:809–13. https://doi.org/10.1038/s41591-022-01703-8 .
doi: 10.1038/s41591-022-01703-8
pubmed: 35228753
pmcid: 9018422
McMurray JJV, Docherty KF, de Boer RA, Hammarstedt A, Kitzman DW, Kosiborod MN, Maria Langkilde A, Reicher B, Senni M, Shah SJ, Wilderäng U, Verma S, Solomon SD. Effect of dapagliflozin versus placebo on symptoms and 6-minute walk distance in patients with heart failure: the DETERMINE Randomized Clinical Trials. Circulation. 2023. https://doi.org/10.1161/CIRCULATIONAHA.123.065061 (Epub ahead of print. PMID: 38059368).
doi: 10.1161/CIRCULATIONAHA.123.065061
pubmed: 38059368
pmcid: 10664793
Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210. https://doi.org/10.1186/s13643-016-0384-4 .
doi: 10.1186/s13643-016-0384-4
pubmed: 27919275
pmcid: 5139140
Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:4l4898. https://doi.org/10.1136/bmj.l4898 .
doi: 10.1136/bmj.l4898
Collaboration TCC. RevMan. Oxford, UK: The Cochrane Collaboration; 2014.
Chapter 9: Summarizing study characteristics and preparing for synthesis | Cochrane Training. Available at: https://training.cochrane.org/handbook/current/chapter-09 . Accessed 25 Dec 2023.
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71. https://doi.org/10.1136/bmj.n71 .
doi: 10.1136/bmj.n71
pubmed: 33782057
pmcid: 8005924
Borlaug BA, Reddy YNV, Braun A, Sorimachi H, Omar M, Popovic D, Alogna A, Jensen MD, Carter R. Cardiac and metabolic effects of dapagliflozin in heart failure with preserved ejection fraction: the CAMEO-DAPA Trial. Circulation. 2023;148(10):834–44. https://doi.org/10.1161/CIRCULATIONAHA.123.065134 (Epub 2023 Aug 3. PMID: 37534453; PMCID: PMC10529848).
doi: 10.1161/CIRCULATIONAHA.123.065134
pubmed: 37534453
pmcid: 10529848
Ibrahim A, Ghaleb R, Mansour H, Hanafy A, Mahmoud NM, Abdelfatah Elsharef M, Kamal Salama M, Elsaughier SM, Abdel-Wahid L, Embarek Mohamed M, Ibrahim AK, Abdel-Galeel A. Safety and efficacy of adding dapagliflozin to furosemide in type 2 diabetic patients with decompensated heart failure and reduced ejection fraction. Front Cardiovasc Med. 2020;7(7):602251. https://doi.org/10.3389/fcvm.2020.602251 (PMID:33426003;PMCID:PMC7793915).
doi: 10.3389/fcvm.2020.602251
pubmed: 33426003
pmcid: 7793915
Palau P, Amiguet M, Domínguez E, Sastre C, Mollar A, Seller J, Garcia Pinilla JM, Larumbe A, Valle A, Gómez Doblas JJ, de la Espriella R, Miñana G, Mezcua AR, Santas E, Bodí V, Sanchis J, Pascual-Figal D, Górriz JL, Baýes-Genís A, Núñez J, DAPA-VO2 Investigators (see Appendix). Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA-VO2): a randomized clinical trial. Eur J Heart Fail. 2022;24(10):1816–26. https://doi.org/10.1002/ejhf.2560 (Epub 2022 Jun 6. PMID: 35604416).
doi: 10.1002/ejhf.2560
pubmed: 35604416
Singh JSS, Mordi IR, Vickneson K, Fathi A, Donnan PT, Mohan M, Choy AMJ, Gandy S, George J, Khan F, Pearson ER, Houston JG, Struthers AD, Lang CC. Dapagliflozin versus placebo on left ventricular remodeling in patients with diabetes and heart failure: the REFORM trial. Diabetes Care. 2020;43(6):1356–9. https://doi.org/10.2337/dc19-2187 (Epub 2020 Apr 3. PMID: 32245746; PMCID: PMC7245350).
doi: 10.2337/dc19-2187
pubmed: 32245746
pmcid: 7245350
McMurray JJV, Wheeler DC, Stefánsson BV, Jongs N, Postmus D, Correa-Rotter R, Chertow GM, Hou FF, Rossing P, Sjöström CD, Solomon SD, Toto RD, Langkilde AM, Heerspink HJL, DAPA-CKD Trial Committees and Investigators. Effects of dapagliflozin in patients with kidney disease, with and without heart failure. JACC Heart Fail. 2021;9(11):807–20. https://doi.org/10.1016/j.jchf.2021.06.017 (Epub 2021 Aug 23. Erratum in: JACC Heart Fail. 2022 Jun;10(6):446-447. PMID: 34446370).
doi: 10.1016/j.jchf.2021.06.017
pubmed: 34446370
Pabel S, Hamdani N, Luedde M, Sossalla S. SGLT2 Inhibitors and Their Mode of Action in Heart Failure-Has the Mystery Been Unravelled? Curr Heart Fail Rep. 2021;18(5):315–28. https://doi.org/10.1007/s11897-021-00529-8 .
doi: 10.1007/s11897-021-00529-8
pubmed: 34523061
pmcid: 8484236
Lee TM, Chang NC, Lin SZ. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med. 2017;104:298–310. https://doi.org/10.1016/j.freeradbiomed.2017.01.035 .
doi: 10.1016/j.freeradbiomed.2017.01.035
pubmed: 28132924
Zhai M, Du X, Liu C, Xu H. The effects of dapagliflozin in patients with heart failure complicated with type 2 diabetes: a meta-analysis of placebo-controlled randomized trials. Front Clin Diabetes Healthc. 2021;2: 703937. https://doi.org/10.3389/fcdhc.2021.703937 .
doi: 10.3389/fcdhc.2021.703937
pubmed: 36994345
pmcid: 10012068
Anderson SL. Dapagliflozin efficacy and safety: a perspective review. Ther Adv Drug Saf. 2014;5(6):242–54. https://doi.org/10.1177/2042098614551938 .
doi: 10.1177/2042098614551938
pubmed: 25436106
pmcid: 4232499
Anitha AP, Balasubramanian S, Ramalingam AG, Samuel Kennady SR, Ganamurali N, Dhanasekaran D, et al. An exploration of the experience of dapagliflozin in clinical practice. Future Sci OA. 2022;8(8):Fso816. https://doi.org/10.2144/fsoa-2022-0038 .
doi: 10.2144/fsoa-2022-0038
pubmed: 36457541
pmcid: 9704035
Blair HA. Dapagliflozin: A review in symptomatic heart failure with reduced ejection fraction. Am J Cardiovasc Drugs. 2021;21(6):701–10. https://doi.org/10.1007/s40256-021-00503-8 .
doi: 10.1007/s40256-021-00503-8
pubmed: 34651263
pmcid: 8639555
Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46. https://doi.org/10.1056/NEJMoa2024816 .
doi: 10.1056/NEJMoa2024816
pubmed: 32970396
Piepoli MF, Hussain RI, Comin-Colet J, Dosantos R, Ferber P, Jaarsma T, Edelmann F. OUTSTEP-HF: randomised controlled trial comparing shortterm effects of sacubitril/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction. Eur J Heart Fail. 2021;23:127–35. https://doi.org/10.1002/ejhf.2076 .
doi: 10.1002/ejhf.2076
pubmed: 33314487
Ali AE, Mazroua MS, ElSaban M, Najam N, Kothari AS, Mansoor T, Amal T, Lee J, Kashyap R. Effect of dapagliflozin in patients with heart failure: a systematic review and meta-analysis. Glob Heart. 2023;18(1):45. https://doi.org/10.5334/gh.1258.PMID:37636033;PMCID:PMC10453961 .
doi: 10.5334/gh.1258.PMID:37636033;PMCID:PMC10453961
pubmed: 37636033
pmcid: 10453961